FUSION PROTEIN OF EXENDIN-4 AND ITS ANALOG, PREPARATION METHOD AND USE THEREOF

  • US 20130142795A1
  • Filed: 06/10/2011
  • Published: 06/06/2013
  • Est. Priority Date: 06/11/2010
  • Status: Active Grant
First Claim
Patent Images

1. A fusion protein, which is obtained by fusing peptide hormone to transport protein via linker, wherein, the said peptide hormone is Exendin-4 or analogue of Exendin-4, and the said peptide hormone is capable of lowering the blood glucose;

  • the said transport protein is the Fc fragment of the immunoglobulin IgG2;

    the said fusion protein is capable of lowering the blood glucose;

    the said peptide hormone comprises the sequence shown by Formula I;


    His-Xaa2-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Xaa10-Ser-Xaa12-Xaa13-Xaa14-Glu-Glu-Glu-Ala-Xaa19-Xaa20-Xaa21-Phe-Ile-Xaa24-Trp-Leu-Xaa27-Xaa28-Gly-Xaa30-Xaa31-Xaa32-Xaa33-Xaa34-Xaa35-Xaa36-Xaa37-Xaa38-Xaa39



    Formula IWherein;

    Xaa2 is Gly, Thr, Ala, Ser, Leu, Ile or Lys;

    Xaa10 is Leu, Ala, Ser, Leu, Ile, Glu or Lys;

    Xaa12 is Lys, Leu, Thr, Ser, Leu, Ile or Cys;

    Xaa13 is Gln, Thr, Ala, Val, Leu, Ile or Lys;

    Xaa14 is Met, Tyr, Thr, Ala, Ser, Ile or Lys;

    Xaa19 is Val, Cys, Ala, Ser, Leu, Ile or Lys;

    Xaa20 is Arg, Thr, Tyr, Ser, Leu, Ile or Lys;

    Xaa21 is Leu, Thr, Ala, Asp, Glu, His or Lys;

    Xaa24 is Glu, Leu, Thr, Ala, Ser, Lys or Ile;

    Xaa27 is Lys, Ala, Ser, Leu, Thr, Ile or Lys;

    Xaa28 is Asp, Thr, Ala, Ser, Leu, Ile or Lys;

    Xaa30 is Gly, Thr, Ala, Ser, Leu, Ile or Arg;

    Xaa31 is Pro, Val, Ser, Ala, Leu, Ile or Lys;

    Xaa32 is Ser, Thr, Glu, Ser, Asp, Lys or Ile;

    Xaa33 is Thr, Ser, Ala, Met, Leu, Ile or Lys;

    Xaa34 is Gly, Thr, Met, Ser, Ile, Leu or Lys;

    Xaa35 is Ala, Thr, Ala, Glu, Leu, Ile or Phe;

    Xaa36 is Pro, Ala, Thr, Ser, Leu, Ile or Cys;

    Xaa37 is Pro, Thr, Ser, Ala, His, Lys or Ile;

    Xaa38 is Pro, Thr, Val, Ser, Leu, Lys or Ile;

    Xaa39 is Ser, Tyr, Ala, Leu, Ser, Ile or Lys.

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×